Education
About Us
Working with TipRanks
Follow Us
Genfit SA (GNFT)
NASDAQ:GNFT
Top Page
Genfit SA
(NASDAQ:GNFT)
48Neutral
Positive Factors
Financial Stability
GENFIT entered into a royalty financing agreement with HealthCare Royalty (HCRx) for up to €185M in total funding, providing financial stability and resources for future projects.
Regulatory Approvals
Iqirvo received FDA approval for the treatment of 2L primary biliary cholangitis (PBC), along with a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), setting the stage for a strong commercial launch.
Negative Factors
Debt Management
Plans to eliminate outstanding convertible debt should provide further capital flexibility for the company moving forward, but could also indicate challenges in financial management.
Regulatory Risks
Key risks to the rating and price target include potential delays in clinical and regulatory timelines and failure to obtain regulatory approvals in additional markets.
Genfit SA (GNFT) vs. S&P 500 (SPY)
Market Cap
$183.84M
Dividend YieldN/A
Average Volume (3M)8.05K
Price to Earnings (P/E)7.6
Beta (1Y)0.56
Revenue Growth243.10%
EPS GrowthN/A
CountryUS
Employees169
SectorHealthcare
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)0.48
Shares Outstanding49,996,185
10 Day Avg. Volume4,757
30 Day Avg. Volume8,051
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.80
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$13.00Price Target Upside254.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Genfit SA Business Overview & Revenue Model
Company DescriptionGenfit SA is a biopharmaceutical company focused on the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases. Headquartered in France, the company operates primarily in the biotechnology and pharmaceuticals sectors. Its core products include drug candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases, as well as diagnostic tools for the identification of these conditions.
How the Company Makes MoneyGenfit SA makes money primarily through the development and commercialization of its pharmaceutical products and diagnostic solutions. The company generates revenue from licensing agreements, partnerships with other pharmaceutical companies, and sales of its diagnostic tools. Key revenue streams include milestone payments and royalties from collaborative agreements, particularly those related to the development and commercialization of its drug candidates. Significant partnerships with larger pharmaceutical companies help enhance its research capabilities and expand its market reach, contributing to its earnings. Additionally, Genfit may also receive government grants or research funding to support its projects, although these are typically a smaller component of its overall revenue model.
Genfit SA Financial Statement Overview
Summary
Genfit SA faces financial challenges with negative profitability and cash flow issues. While revenue has rebounded, it remains below previous levels. The balance sheet shows some stabilization, but high debt is a concern.Income Statement
Genfit SA's income statement shows a challenging period with significant fluctuations. The gross profit margin remained strong, but the net profit margin was negative due to substantial losses, reflecting ongoing financial challenges. Revenue showed a rebound in 2023 from 2022 but remains below 2021 levels, indicating instability. The EBIT and EBITDA margins were both negative, underscoring operational inefficiencies and ongoing struggles to achieve profitability.42
Neutral
Balance Sheet
The company's balance sheet reflects a moderate position. The debt-to-equity ratio has improved, but remains an area of concern, indicating a reliance on debt financing. The return on equity has been negative, reflecting recent losses. However, the equity ratio has improved from negative to positive, showcasing some stability in its financial structure.55
Neutral
Cash Flow
Cash flow analysis reveals significant challenges for Genfit SA. The free cash flow growth rate is negative, indicating cash outflows exceeding inflows. The operating cash flow to net income ratio is negative due to losses, and the free cash flow to net income ratio is unfavorable, highlighting ongoing cash management issues and the need for improved cash flow generation.38
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 78.19M | 28.57M | 20.20M | 80.07M | 765.00K | 30.84M | Gross Profit |
| 77.32M | 28.22M | 19.95M | 79.91M | 563.00K | 30.66M | EBIT |
| 14.89M | -26.58M | -27.55M | 76.74M | -77.79M | -57.83M | EBITDA |
| 24.65M | -22.24M | -23.60M | 34.91M | -91.14M | -51.02M | Net Income Common Stockholders |
| 22.27M | -28.89M | -23.72M | 67.26M | -101.22M | -65.14M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 77.79M | 77.79M | 140.55M | 258.76M | 171.03M | 276.75M | Total Assets |
| 173.87M | 173.87M | 215.54M | 281.72M | 198.61M | 309.85M | Total Debt |
| 70.18M | 70.18M | 75.28M | 74.23M | 185.69M | 183.62M | Net Debt |
| -7.61M | -7.61M | -60.73M | -184.52M | 14.66M | -93.13M | Total Liabilities |
| 105.92M | 105.92M | 121.01M | 162.62M | 214.78M | 225.79M | Stockholders Equity |
| 67.95M | 67.95M | 94.53M | 119.10M | -16.16M | 84.06M |
| Cash Flow | Free Cash Flow | ||||
| -42.69M | -57.92M | -72.64M | 99.38M | -97.27M | -49.71M | Operating Cash Flow |
| -41.54M | -55.43M | -72.64M | 99.92M | -96.37M | -47.68M | Investing Cash Flow |
| -1.14M | 2.23M | -46.27M | -3.38M | -966.00K | 327.00K | Financing Cash Flow |
| -7.56M | -5.10M | -3.79M | -8.92M | -8.26M | 116.86M |
Genfit SA Technical Analysis
Neutral
3.67
Price Trends
3.70
Negative
3.95
Negative
4.29
Negative
Market Momentum
-0.04
Negative
52.34
Neutral
64.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNFT, the sentiment is Neutral. The current price of 3.67 is above the 20-day moving average (MA) of 3.56, below the 50-day MA of 3.70, and below the 200-day MA of 4.29, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 52.34 is Neutral, neither overbought nor oversold. The STOCH value of 64.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GNFT.
Genfit SA Risk Analysis
Genfit SA disclosed 73 risk factors in its most recent earnings report. Genfit SA reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Genfit SA Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $3.47B | ― | -39.22% | ― | ― | -31.37% | |
54 Neutral | $7.24B | ― | -80.35% | ― | ― | -10.89% | |
49 Neutral | $6.85B | 0.81 | -52.75% | 2.49% | 20.08% | 1.28% | |
48 Neutral | $183.84M | 7.58 | 26.13% | ― | 243.10% | ― | |
48 Neutral | $1.18B | ― | -78.34% | ― | ― | -70.45% | |
42 Neutral | $2.93B | ― | -17.90% | ― | ― | -10.27% |
* Healthcare Sector Average
Performance Comparison
GNFT
Genfit SA
3.67
0.11
3.09%
MDGL
Madrigal Pharmaceuticals
327.87
72.13
28.20%
VKTX
Viking Therapeutics
25.65
-53.85
-67.74%
AKRO
Akero Therapeutics
42.72
18.65
77.48%
ETNB
89bio
8.08
-2.65
-24.70%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.